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ABSTRACT 
Objective: The intension of the present study includes fabrication and optimization of mouth dissolving film loaded with Chlorothalidone by 
solvent evaporation techniques using two components and their three levels as multilevel Categoric design. 
Methods: Major problem associated with the development of film loaded with BCS class II drug is to increase its solubility. Here the Chlorothalidone 
solubility achieved by co-solvents, such as methanol. After dissolving the drug in co-solvent, this drug solution is poured into an aqueous dispersion 
of Hydroxypropyl Methylcellulose E5 (HPMC E5) and Polyethylene glycol 400 (PEG 400). The two independent variables selected are factor A 
(concentration of HPMC E5) and factor B (concentration of PEG 400) was selected on the basis of preliminary trials. The percentage drug release 
(R1), Disintegration time in sec (R2) and folding endurance (R3) were selected as dependent variables. Here HPMC E5 used as a film former, PEG 
400 as plasticizer, mannitol as bulking agent, Sodium starch glycolate as a disintegrating agent, tween 80 as the surfactant, tartaric acid as saliva 
stimulating agent, sodium saccharin as a sweetener and orange flavour etc. These fabricated films were evaluated for physicochemical properties, 
disintegration time and In vitro drug release study. 
Results: The formulation F6 has more favorable responses as per multilevel categoric design is % drug release about 98.95 %, average 
disintegration time about 24.33 second and folding endurance is 117. Thus formulation F6 was preferred as an optimized formulation. 
Conclusion: The present formulation delivers medicament accurately with good therapeutic efficiency by oral administration, this mouth dissolving 
films having a rapid onset of action than conventional tablet formulations.  
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INTRODUCTION 
Around all drug delivery systems, drug administration by the oral 
route is being considered more suitable. Various fast disintegrating 
drug delivery systems developed instead of capsules, tablet and 
syrups for the patient who having struggled in swallowing. Mouth 
dissolving film is preferable path to increase patient compliance [1]. 
Mouth dissolving film becomes a trending drug delivery system 
because of its various merits. On contact with saliva, it disintegrates 
within a minute seconds, without the demand of water, making them 
particularly appropriate for pediatric and geriatric patients. Drug 
from film directly reaches into systemic circulation, thus it avoids 
the first-pass effect [2]. 
Chlorothalidone is a phthalamide derivative of benzene 
sulphonamide, Thiazide diuretics are preferred pharmacological 
treatments for uncomplicated hypertension. Chlorothalidone is used 
in the present study and widely accepted for its excellent 
antihypertensive as well as anti-diuretic effect. It not only improves 
blood pressure but also swelling by preventing water absorption 
from the kidneys through inhibition of the Na+/Cl− symporter in the 
distal convoluted tubule cells in the kidney [3]. 
 
 
Fig. 1: Chlorthalidone 
Multilevel categoric design generates trials that ultimately 
minimizes cost of an investigation. The outcomes of independent 
variables were studied on 9 different runs generated by the 
software. The rational of the present study is to enhance the 
bioavailability of Chlorothalidone by formulating as mouth 
dissolving film. 
MATERIALS AND METHODS 
Materials 
Chlorothalidone (Gift sample of Aurobindo Pharma Ltd research 
Centre II, Hyderabad), HPMC E3, E5 (DOW chemicals), PEG 400 and 
Tween 80 LR (SDFCL Mumbai), Tartaric acid (Merck Chemicals Ltd., 
Mumbai), Mannitol (Roguette Freres), Sodium Saccharin, orange 
flavor (Burgoyne Burbidges and Co, Mumbai, India). All other 
reagents of analytical grade were used.  
Methods 
Drug excipients compatibility studies by Infrared spectroscopy (IR) 
The IR absorption spectra of the pure drug and their physical 
mixture with accidents were recorded in the range of 4000-400 
cm−1 by using an IR spectrophotometer (PerkinElmer) [4]. 
Preliminary trials for choosing a suitable polymer and 
plasticizer 
Preliminary trials of formulation development were carried out 
using HPMC E3, E5 and sodium alginate etc. as film-forming agent 
with 2.5 % w/v, 3.0 % w/v and 3.5 % w/v etc. From that sodium, 
alginate film was easily prone to breaking whereas HPMC E3 shows 
thin film formation. HPMC E5 has good film-forming property, 
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satisfied disintegration time and good folding-endurance. In a 
preliminary feasibility study amount, less than 0.4 % w/v of PEG 
400 shows poor flexibility, whereas above 0.8 % w/v shows sticky 
appearance. So that further formulation development was carried 
out between 0.4 % w/v to 0.8 % w/v. 
Formulation of drug-loaded oral film 
Films were prepared as per the formula given in table 1. Solvent 
casting method was used for the preparation of films using polymers 
(HPMC E5). Initially, the polymer was weighed accurately and 
dissolved in half the amount of water and mixed on a magnetic 
stirrer. The drug was weighed and dissolved in 1 ml of methanol. 
Tartaric acid and sodium saccharin were both dissolved in the 
remaining amount of water. This solution was added to the 
polymeric solution and stirred well using a magnetic stirrer to 
obtain a homogeneous solution, followed by the addition of PEG 400 
as a plasticizer and orange flavor. This solution was allowed to stand 
for 30 min for de-aeration of the solution. The solution was then cast 
in a petri dish and kept in a hot air oven for 8-10 h at 50 °C. After 
drying, films were removed. Thus the obtained large film was cut 
into 3 × 3 cm2. The film was stored in a butter paper covered with 
aluminum foil and stored in a desiccator. 
Formulation of polymeric mouth dissolving film of 
chlorothalidone using a multilevel categoric design by design 
expert® 12 software 
In order to optimize the independent variable, factor A 
(concentration of HPMC E5) and factor B (concentration of PEG 400) 
was selected for further development. These variables were taken at 
three different levels, i.e. lower, medium and higher level. Those 
variables were stipulated on the basis of the preliminary feasibility 
study earlier to the design of experiments.  
The dependent variables or response evaluated were % drug 
release, disintegration time in second and folding endurance, etc. 
The total 9 trials were generated by Design-Expert®12 software; the 
experimental data were analyzed using analysis of variance 
(ANOVA) by fitting responses in the respective run [5]. 
 
Table 1: Composition of chlorothalidone loaded mouth dissolving films (F1-F9) 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Chlorothalidone 98.38 98.38 98.38 98.38 98.38 98.38 98.38 98.38 98.38 
Mannitol 15 15 15 15 15 15 15 15 15 
HPMC E5 250 250 250 300 300 300 350 350 350 
SSG 10 10 10 10 10 10 10 10 10 
PEG 400 40 60 80 40 60 80 40 60 80 
Sod. Saccharin 10 10 10 10 10 10 10 10 10 
Tartaric acid 10 10 10 10 10 10 10 10 10 
Orange flavour Qs Qs Qs Qs Qs Qs Qs Qs Qs 
Water (ml) 9 ml 9 ml 9 ml 9 ml 9 ml 9 ml 9 ml 9 ml 9 ml 
Methanol 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 
 
Dose calculation of the amount of drug per batch  
Dose of drug per film =12.5 mg 
An area of one film = 9 cm2  
Area of petri plate = 70.84 cm2  
Drug to be added per batch
= Dose of drug per film × Area of petri plate
÷ Area of one film  
= (12.5 × 70.84)/9 = 98.38 mg. 
Standard calibration curve of chlorothalidone 
100 mg of Chlorothalidone was dissolved in 10 ml of 6.8 pH phosphate 
buffer and volume was made up to 100 ml with the 6.8 pH phosphate 
buffer (1000 µg/ml). 10 ml of the above solution was diluted up to 100 
ml with 6.8 pH phosphate buffer (100 µg/ml). Then by serial dilution 
solutions with concentrations 5µg/ml, 10µg/ml, 15µg/ml, 20µg/ml, 
25µg/ml and 30µg/ml were prepared. Absorbance was measured on a 
Shimadzu 1800 Double Beam Spectrophotometer in the range of 200 
to 400 nm. Finally, a spectrum and wavelength of maximum 
absorption were recorded [6]. 
Evaluation of chlorothalidone loaded mouth dissolving film 
Appearance 
Formulated mouth dissolving films were assessed for their appearances 
either they are transparent or opaque by visual inspection or surface 
texture was assessed by contact or feel of the film [7]. 
Weight variation  
The individual weight each of 10 films of 3×3 cm2for each 
formulation on an electronic weighing balance. The average weight 
was calculated [8]. 
Thickness 
The average thickness of the mouth dissolving film was determined 
by using digital Vernier Calliper (Digimatic, Mitutoyo, Japan) with a 
least count of 0.01 mm. The thickness was determined at five 
different places of the film and the average was taken and the 
standard deviation was calculated [9]. 
Surface pH 
The surface pH was determined by placing one mouth dissolving 
film in a glass vial, adding 1 ml of distilled water and wait for 30 Sec. 
The pH value obtained by bringing electrodes of pH meter (Lab, 
India) in contact with the moistened surface of the film. All 
measurements were performed in triplicate. It is essential that the 
strip should have an almost uniform pH value [10]. 
Folding endurance 
It was determined by repeatedly collapsing the film of uniform 
cross-sectional area and thickness until it breaks. The number of 
times film was folded without breaking computed as the folding 
endurance value. This test ensures the tensile strength of the film. 
The number of times the film could be folded at the same place 
without breaking/cracking gave the value of folding endurance [11]. 
Percent elongation 
At the point when stress is applied to the film sample stretches and is 
alluded to as a strain. Strain is basically the deformation of the film 
divided by the original dimension of the film. Generally, the flexibility 
of the film increases as the plasticizer concentration increases. 
Percentage elongation was calculated by measuring the increase in the 
length of the film after tensile strength measurement by using the 
following formula [12]. At the point when stress is applied to the film 
sample stretches and is alluded to as a strain. 
Percentage Elongation = L − L0	 × 100 ÷ L0 
Where L = Final length 
L0 = initial length 
Percentage of moisture loss 
The percent moisture loss was evaluated by setting the prepared 
film in desiccators containing anhydrous calcium chloride. 
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Following three days, the film was taken and reweighed. The 
percent moisture loss calculated was determined to utilize the 
following formula [13]. 
% Moisture loss =
Initial weight
Initial weight −  Final weight
 × 100 
Drug content 
A film of size 3 × 3 cm2 is cut and put in 100 ml of the volumetric 
flask containing solvent. This is then shaken in a mechanical shaker 
for 1 hour to get a homogeneous solution and filtered. The drug is 
determined spectroscopically after appropriate dilution. 
Chlorthalidone concentrations were assayed spectrophotometrically 
at 275.8 nm [14]. 
In vitro dissolution study 
The dissolution test was accomplished using to USP type I Basket 
apparatus (Electrolab Dissolution tester, EDT-08Lx). The 
dissolution medium was 900 ml of 6.8 pH phosphate buffer, 
maintained at 37±10 °C and stirred at 75 RPM. Each square cut 
film sample (3 cm x 3 cm) was placed into the dissolution 
medium and appropriate aliquots were withdrawn at 3, 6, 9, 12 
and 15 minute time intervals and again replaced with the same 
volume of dissolution media. The sample was filtered through 
Whatman filter paper for all the batches and analyzed 
spectrophotometrically at 275.8 nm (Model UV-1800 UV Visible 
spectrophotometer, Shimadzu, Japan). Sink conditions were 
maintained during the experiment. The dissolution test was 
performed in triplicate for each batch [15]. 
In-vitro disintegration study 
The film size to be required for delivering a dose (3×3 cm2) was 
placed on a glass Petri dish containing 10 ml of 6.8 pH phosphate 
buffer. The minimum time required for mouth dissolving film to 
break was noted as in vitro disintegration time [16]. 
Stability study 
The stability study of the optimized formulation was carried out by 
storage conditions specified by ICH known as ICH guidelines. The single 
film wrapped in butter paper followed by packing in Aluminium foil and 
placed in accelerated stability conditions at 40±2 °C and 75±5% RH for 
the period of 6 mo. Samples were taken at regular intervals and analyzed 
for folding endurance, drug content and % drug release [17].  
RESULTS AND DISCUSSION 
Drug excipients compatibility study by infrared spectroscopy (IR) 
IR spectrum of Chlorothalidone and physical mixture with excipients 
was recorded and it was found in accordance with the reported 
peaks. It is shown in below fig. (fig. 2 and 3). The IR spectra of 
Chlorothalidone comply with its chemical structure and show peaks 
for principal groups. The structural assignments for the 
characteristic absorption bands are listed in the following table 2. 
In physical mixtures of Chlorothalidone and excipients, there was 
neither masking of single characteristic peak nor the existence of an 
additional peak in drug spectra. The overall correlation in the two 
spectra was 0.9999. So it was concluded that all excipients were 
compatible with each other. 
Optimization of the selected independent variable by design-
expert®12 software 
In a preliminary feasibility study, films were prepared with different 
polymers like HPMC (E3, E5) and sodium alginate. Finally, from these 
trials made and results obtained, HPMC E5 and PEG 400 were selected 
with different levels for further formulation development. The polymer 
HPMC E5 and plasticizer PEG 400 were taken at three different level, i.e. 
lower, medium and higher level. Thus, total 9 trails were obtained by 
Design-Expert®12 software and the dependent variables or response 
evaluated were % drug release in 15 min, disintegration time (second) 
and folding endurance (number of folds) are shown in table 3. 
 
 
Fig. 2: IR spectrum of pure chlorthalidone 
 
 
Fig. 3: IR Spectrum of chlorothalidone and excipients 
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Table 2: Infrared spectral assignment for chlorothalidone 
S. No. Functional group Reported frequency (cm-1) Frequency for drug (cm-1)  Frequency physical mixture of drug and 
excipients (cm-1) 
1 C=O (S) 1630-1980 1828.59 1828.28 
2 Primary NH (S) 3100-3500 3361.92 3361.92 
3 SO2 (S) 1000-1100 1039.63 1037.34 
4 OH (S) 3200-3400 3255.84 3253.55 
 
Table 3: Optimization parameters of chlorothalidone loaded mouth dissolving films 
Run Independent variables Dependent variables 
Factor 1 
HPMC E5 (mg) 
Factor 2 PEG 400  
(mg) 




F1 250 40 99.12 19.22 49 
F2 250 60 99.56 17.87 64 
F3 250 80 99.93 16.62 79 
F4 300 40 98.17 31.12 96 
F5 300 60 98.48 27.84 104 
F6 300 80 98.95 24.33 117 
F7 350 40 89.46 46.16 125 
F8 350 60 91.87 39.41 131 





Fig. 4: 3 D surface plots (a-c) showing the effect of the selected independent variable on dependent variable viz. % Drug release (R1), 
disintegration time (R2) and folding endurance (R3) 
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Table 4: ANOVA for chlorothalidone mouth dissolving film from multilevel categoric design 
Source d. f. Sum square Mean square F value P value 
 % Drug release in 15 Min (Response 1)  
A-HPMC E5 2 104.38 52.19 39.01 0.0024 
B-PEG 400 2 6.81 3.40 2.54 0.1938 
Model 4 111.18 27.80 20.77 0.0061 
Disintegration time Sec (Response 2) 
A-HPMC E5 2 758.80 379.40 87.40 0.0005 
B-PEG 400 2 67.73 33.86 7.80 0.0416 
Model 4 826.52 206.63 47.60 0.0013 
Folding endurance (Response 3) 
A-HPMC E5 2 7053.56 3526.78 238.65 0.0001 
B-PEG 400 2 729.56 364.78 24.68 0.0056 
Model 4 7783.11 1945.78 131.67 0.0002 
 
Numerical optimization 
Table 5: Constraints for selected independent variables 
Name Goal Lower limit Upper limit Lower weight Upper weight Importance 
A: HPMC E5 is in range 250 350 1 1 3 
B: PEG 400 is in range 40 80 1 1 3 
Dissolution in 15 Min Maximize 89.46 99.93 1 1 5 
Disintegration time (Sec) Minimize 16.62 46.16 1 1 5 
Folding endurance (Folds) Maximize 49 140 1 1 5 
 
Table 6: Different solutions for 9 combinations 
Number HPMC E5 PEG 400 Dissolution in 15 min Disintegration time Folding endurance Desirability  
1 300 80 99.602 24.561 117.111 0.809 Selected 
2 300 60 98.526 27.468 104.778 0.695  
3 250 80 100.606 14.701 75.444 0.662  
4 300 40 97.472 31.261 95.111 0.580  
5 250 60 99.529 17.608 63.111 0.524  
6 350 80 92.932 37.138 143.444 0.466  
7 350 60 91.856 40.044 131.111 0.350  
8 250 40 98.476 21.0401 53.444 0.328  
9 350 40 90.802 43.838 121.444 0.200  
 
Table 7: Regression analysis of response R1, R2 and R3 
Factorial model R2 Adjusted R2 Predicted R2 SD % CV 
R1 % Drug release in 15 min 0.9541 0.9082 0.7675 1.16 1.20 
R2 Disintegration time (sec) 0.9794 0.9588 0.8958 2.08 7.27 
R3 folding endurance (folds) 0.9925 0.9849 0.9618 3.84 3.82 
 
 
Fig. 5: UV spectrum of chlorthalidone 
 
Determination of λ max 
A concentration of 30 μg/ml was prepared from standard 
Chlorothalidone solution and scanned by a UV-visible 
spectrophotometer in the range of 200-400 nm using 6.8 pH 
phosphate buffer as blank then the maximum wavelength (λ-max) 
was determined (fig. 5). 
Standard calibration curve of chlorthalidone in 6.8 pH 
phosphate buffer 
Chlorthalidone showed maximum absorption at wavelength 275.8 
nm in 6.8 pH phosphate buffer. A standard curve was plotted by 
taking absorption of diluted stock solutions (5, 10, 15, 20, 25 and 30 
μg/ml) at wavelength 275.8 nm [18]. 
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Table 8: Standard calibration curve of chlorothalidone in 6.8 pH phosphate buffer 
S. No. Concentration (μg/ml) Absorbance at 275.8 nm 
1 5 0.0598 
2 10 0.1507 
3 15 0.2102 
4 20 0.2931 
5 25 0.3675 
6 30 0.4178 
 
 
Fig. 6: Calibration curve of chlorothalidone in 6.8 pH phosphate buffer 
 
Preparation and physical characterization of chlorothalidone 
mouth dissolving film 
Preliminary feasibility trails were prepared with different polymers 
like HPMC (E3, E5) and sodium alginate. Finally, from these trials 
made and results obtained, HPMC E5 and PEG 400 were selected 
with different levels for further formulation development. 
Evaluation of films 
Appearance 
In preliminary trails, film from sodium alginate shows brittle nature, 
whereas HPMC E3 shows thin film-forming ability. Finally, the film 
prepared with HPMC E5 showed good film-forming property. Mouth 
dissolving films were visually evaluated, all films F1 to F9 shows 
good transparency, homogeneity and smooth appearance. All the 
formulations showed no change in the properties at the end of 6 the 
month time period [19]. 
 
 




The weight of mouth dissolving film was determined by using digital 
weighing balance and the average weight of all film (F1 to F9) was 
found to be in the range of 55-73 mg. Some films shows less than 5% 
variation in the weight, maybe due to lack of flat surface in petri plate 
or slant surface of hot air oven. Form a result, it was observed that the 
increase in polymer–plasticizer ratio weight of films also increased [8].  
Thickness 
The thickness of the mouth dissolving films was measured using digital 
Vernier caliper and the average thickness of all Fast dissolving film was 
found in between 0.153–0.349 mm (n=3). All films show a standard 
deviation of average thickness in the range 0-5 % that may be due to 
good positioning during the solvent evaporation process [20]. 
Surface pH 
The surface pH was noted by pH meter near the surface of the fast-
dissolving film and allowing equilibrating for 30 Sec and the surface 
pH of all fast dissolving film was found to in between 6.59-6.89 pH 
(n=3). All batches show pH towards a neutral range, which is 
evidence for the absence of oral mucosal irritation [10]. 
Folding endurance 
The average folding endurance of all Fast dissolving films was 
ranging from 49-140. It was observed that folding endurance 
increases with increasing plasticizer concentration [11].  
Percentage elongation  
The average % elongation for formulation F1 to F9 was found in the 
range of 10.79±0.32 % to 19.23±0.68 %. Percentage elongation was 
decreased with increasing polymer concentration [12].  
Percentage of moisture loss 
The percentage of moisture loss of formulations F1 to F9 was 
estimated. The average % moisture loss found in the range of 
1.471±0.008 % to 1.974±0.004 %. All formulation shows moisture 
within the limits that is evidence for the stability of the film against 
microbial growth [13]. 
Drug content  
The percentage of drug content for all trails F1 to F9 was 
obtained in the range of 98.21±0.27 % to 99.87±0.20 %. All films 
having drug content within the limits, therefore it can be 
concluded that mouth dissolving film will deliver an accurate 
dose of medicament [15]. 
In vitro dissolution study  
In vitro dissolution investigation of Chlorothalidone loaded mouth 
dissolving film was carried out in pH 6.8 phosphate buffer solution 
(shown in fig. 8). Drug release from F1 to F9 was more than 90 % 
within 15 min. It was observed that the drug release is slower with 
increasing polymer concentration [21].  
In-vitro disintegration study 
Mouth dissolving film with dimension 3 x 3 cm2 size taken and 
disintegration time observed visually. Average disintegration times 
of three fast dissolving films were calculated. Disintegration time 
ranges from 16-46 seconds, which indicates the disintegration time 
of film obtained within a minute. As polymer concentration 
increases disintegration time also increases, but PEG 400 minimizes 
disintegration time [16]. 
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Table 9: Formulation result from trails batches 








% Moisture loss 
(n=3) 
Drug content (%) 
(n=3) 
F1 55.12±0.076 0.153±0.017 6.81±0.88 18.81±0.74 1.794±0.001 98.97±0.59 
F2 57.56±0.054 0.162±0.027 6.84±0.54 19.23±0.68 1.974±0.004 99.29±0.84 
F3 59.98±0.015 0.164±0.012 6.89±0.15 18.13±0.41 1.663±0.001 99.72±0.27 
F4 61.41±0.044 0.241±0.021 6.78±0.24 14.27±0.33 1.659±0.007 99.17±0.88 
F5 63.87±0.037 0.249±0.014 6.92±0.37 16.89±0.87 1.513±0.004 99.22±0.56 
F6 66.61±0.043 0.253±0.03 6.96±0.66 14.72±0.57 1.669±0.003 98.21±0.27 
F7 67.76±0.028 0.327±0.082 6.59±0.69 11.67±0.92 1.539±0.002 99.10±0.81 
F8 70.31±0.092 0.349±0.038 6.66±0.52 10.79±0.32 1.471±0.008 99.19±0.66 
F9 72.84±0.019 0.339±0.043 6.81±0.13 13.07±0.63 1.739±0.007 99.87±0.20 
*All data are given in mean±SD 
 
Table 10: In vitro drug release profiles of mouth dissolving film 
Batches % Drug release 
3 Min 6 Min 9 Min 12 Min 15 Min 
F1 16.12 44.23 69.27 84.64 99.12 
F2 19.74 46.32 74.11 87.45 99.56 
F3 21.46 49.22 79.41 91.37 99.93 
F4 9.45 32.04 57.41 82.66 98.17 
F5 11.25 37.44 61.23 86.74 98.48 
F6 15.12 41.16 66.87 84.43 98.95 
F7 5.46 19 50.41 71.22 89.46 
F8 8.22 24 54.44 77.54 91.87 
F9 10.49 29 62.96 81.41 94.26 
 
 
Fig. 8: Comparison of in vitro dissolution profile between F1 to F9 
 
Table 12: Accelerated stability study of optimized trail F6 
Parameter for study The maintained temperature at 40±2 °C and relative humidity (RH) at 75%±5% RH 
Initial After1 mo After 3 mo After 6 mo 
% Drug release 98.95 98.91 98.82 98.49 
Drug content (%) (n=3) 98.21±0.27 98.71±0.41 98.11±0.87 98.49±0.62 
Folding endurance 117 121 114 116 
*Data are given in mean±SD, n=3  
 
Stability study 
Optimized formulation (F6) do not show changes in appearance, 
folding endurance, drug content and In-vitro % drug release after 
placing in the Accelerated Stability Studies. Hence the formulation 
(F6) was indicated to be stable [17]. 
CONCLUSION 
Mouth dissolving films of Chlorothalidone were fabricated with 
HPMC E5 and PEG 400 by using the solvent evaporation technique. 
All formulation shows a good drug release profile, drug content, 
folding endurance, disintegration time, pH and % elongation etc.  
Among that formulation, F6 shows better drug release, 
disintegration time, folding endurance and found to be a good stable 
at accelerated stability condition specified by ICH.  
So that F6 batch considered as optimized formulation. Hence mouth 
dissolving film of Chlorothalidone was found to be suitable for the 
management of edema and hypertension. 
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